Generic Glatiramer Matches Branded Copaxone in Clinical Efficacy (CME/CE)
(MedPage Today) -- But don't expect a break from the high annual cost (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 14, 2015 Category: Neurology Source Type: news
Teva’s Copaxone gets Japanese approval for multiple sclerosis relapse prevention
The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for Israel-based Teva Pharmaceutical Industries' once-daily Copaxone (glatiramer acetate injection) 20mg injection for prevention of multiple sclerosis relapse. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 29, 2015 Category: Pharmaceuticals Source Type: news
Teva Announces Approval of COPAXONE(R) in Japan for the Prevention of Relapse of Multiple Sclerosis
JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) announced today the approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) of once-daily COPAXONE® (glatiramer acetate injection... Biopharmaceuticals, Neurology, RegulatoryTeva Pharmaceutical, COPAXONE, glatiramer, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 28, 2015 Category: Pharmaceuticals Source Type: news
Teva's MS drug Copaxone has strong second-quarter sales
JERUSALEM (Reuters) - Teva Pharmaceutical Industries , which this week revealed plans to buy Allergan's generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition. (Source: Reuters: Health)
Source: Reuters: Health - July 30, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Alcon’s sluggish Q2 hits Novartis
(Reuters) — A weak performance from eyecare division Alcon, plus the strong dollar, hit Novartis (NYSE:NVS) in the 2nd quarter, scuppering hopes that the Swiss drugmaker would raise its 2015 financial outlook.
The difficulties at Alcon reflected lower sales of contact lenses, intraocular lenses and surgical equipment, offsetting a solid showing in pharmaceuticals and an impressive sales jump within the Sandoz generics business.
With overall quarterly core net income falling short of expectations, Novartis lowered its full-year sales forecast for Alcon and raised guidance for Sandoz.
The unchanged overall outlook for th...
Source: Mass Device - July 21, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: MassDevice Earnings Roundup Optical/Ophthalmic Alcon Inc. Novartis AG Source Type: news
First generic multiple sclerosis drug, made in Cambridge, launches
Cambridge-based Momenta Pharmaceuticals and partner Sandoz announced plans late yesterday to launch the first generic drug in the U.S. to treat multiple sclerosis, priced 15 percent less than the branded version of the drug.
Momenta (Nasdaq: MNTA) developed the generic of the 20 milligram dosage of Copaxone, a once-a-day injectable drug by Israel-based Teva Pharmaceuticals (Nasdaq: TEVA) that generated $4.2 billion in revenue last year. The Cambridge biotech has partnered with Sandoz, the generics… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 19, 2015 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news
US court finds Teva's Copaxone patent invalid again: Natco Pharma
Natco Pharma, a city-based drug maker, today said the US Court of Appeals for Federal Court has again found one of the patents of Teva's Copaxone as invalid. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 19, 2015 Category: Pharmaceuticals Source Type: news
Novartis’s Sandoz introduces generic version of Teva’s multiple sclerosis drug
Novartis subsidiary Sandoz has introduced Glatopa in the US, a generic version of Teva's Copaxone (glatiramer acetate injection) 20mg/ml one-time-daily multiple sclerosis (MS) therapy. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 18, 2015 Category: Pharmaceuticals Source Type: news
Novartis’ Sandoz introduces generic version of Teva’s multiple sclerosis drug
Novartis subsidiary Sandoz has introduced Glatopa in the US, a generic version of Teva's Copaxone (glatiramer acetate injection) 20mg/ml one-time-daily multiple sclerosis (MS) therapy. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 18, 2015 Category: Pharmaceuticals Source Type: news
U.S. appeals court again invalidates Teva's MS drug patent
NEW YORK (Reuters) - A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version. (Source: Reuters: Health)
Source: Reuters: Health - June 18, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Glatiramer Acetate Industry in Global & Chinese Regions Forecast...
ReportsnReports.com adds “2015 Glatiramer Acetate Industry Report – Global and Chinese Market Scenario” to its store.(PRWeb May 21, 2015)Read the full story at http://www.prweb.com/releases/glatiramer-acetate-market/global-and-chinese-2020/prweb12739431.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 21, 2015 Category: Pharmaceuticals Source Type: news
Glatopa (glatiramer acetate injection) for the Treatment of Multiple Sclerosis
Glatopa (glatiramer acetate injection, formerly M356) is the first substitutable generic drug approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2015 Category: Pharmaceuticals Source Type: news
Glatopa (glatiramer acetate Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 5, 2015 Category: Drugs & Pharmacology Source Type: news
Study shows MS drugs are cost effective
The six year data from the ten year Risk-sharing Scheme project has found that the beta interferon drugs and glatiramer acetate are cost effective treatments for the NHS. People taking one of these drugs showed a slower increase in EDSS measures than predicted for untreated controls.
Pharmaceutical Journal
Risk-sharing Scheme (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 23, 2015 Category: Neurology Source Type: news
Less frequent glatiramer acetate (Copaxone)
People who took the three times a week version of Copaxone for three years did better than those who were in the placebo group for the first year of the trial. Presented at the American Academy of Neurology (AAN) meeting.
MPR
Glatiramer acetate (Copaxone) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 22, 2015 Category: Neurology Source Type: news
